340B PATIENTS Act of 2024
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The 340B PATIENTS Act of 2024 is a Senate bill introduced in the 118th Congress related to health policy. The bill was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions on September 11, 2024. However, the bill ultimately failed or expired without further legislative action. No official summary or full text is publicly available, limiting detailed analysis of its specific provisions or intended changes to the 340B drug pricing program or related patient protections.
This bill aimed to address issues within the 340B drug pricing program but did not advance beyond committee referral and is no longer active in the 118th Congress.
- The bill is titled the 340B PATIENTS Act of 2024 and was introduced in the Senate.
- It was referred to the Senate Committee on Health, Education, Labor, and Pensions after initial readings.
- The bill failed or expired without further action and no official summary or full text is available.
Due to the lack of detailed text or summary, it is unclear who specifically would benefit; however, given the bill's title, potential beneficiaries might have included patients, healthcare providers, and entities involved in the 340B drug pricing program.
Without full text or summary, potential concerns include unknown implementation challenges, oversight mechanisms, funding requirements, or regulatory authority changes related to the 340B program.
The bill was introduced during the 118th Congress and referred to a key Senate committee overseeing health policy. Its failure to advance suggests it did not gain sufficient legislative support or priority before the session ended.
Hidden impact flags detected: 1
GovScope reviewed 1 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
If enacted, the bill could have influenced drug pricing policies and patient access under the 340B program, potentially affecting healthcare costs and provider operations. However, these effects cannot be confirmed due to lack of detailed provisions.
The absence of publicly available bill text and summary highlights a transparency gap that limits public and stakeholder ability to evaluate the bill's impact. Tracking such gaps is important for government accountability and informed legislative debate.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.